These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12525512)

  • 1. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
    Tolcher AW; Ochoa L; Hammond LA; Patnaik A; Edwards T; Takimoto C; Smith L; de Bono J; Schwartz G; Mays T; Jonak ZL; Johnson R; DeWitte M; Martino H; Audette C; Maes K; Chari RV; Lambert JM; Rowinsky EK
    J Clin Oncol; 2003 Jan; 21(2):211-22. PubMed ID: 12525512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
    Rodon J; Garrison M; Hammond LA; de Bono J; Smith L; Forero L; Hao D; Takimoto C; Lambert JM; Pandite L; Howard M; Xie H; Tolcher AW
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):911-9. PubMed ID: 18301896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
    Helft PR; Schilsky RL; Hoke FJ; Williams D; Kindler HL; Sprague E; DeWitte M; Martino HK; Erickson J; Pandite L; Russo M; Lambert JM; Howard M; Ratain MJ
    Clin Cancer Res; 2004 Jul; 10(13):4363-8. PubMed ID: 15240523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
    Xie H; Audette C; Hoffee M; Lambert JM; Blättler WA
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1073-82. PubMed ID: 14634038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
    Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology evaluation: cantuzumab mertansine, ImmunoGen.
    Smith SV
    Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
    Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
    Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
    Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
    J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
    Sauter A; Kloft C; Gronau S; Bogeschdorfer F; Erhardt T; Golze W; Schroen C; Staab A; Riechelmann H; Hoermann K
    Int J Oncol; 2007 Apr; 30(4):927-35. PubMed ID: 17332932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
    Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
    J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
    Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
    Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
    Geller JI; Pressey JG; Smith MA; Kudgus RA; Cajaiba M; Reid JM; Hall D; Barkauskas DA; Voss SD; Cho SY; Berg SL; Dome JS; Fox E; Weigel BJ
    Cancer; 2020 Dec; 126(24):5303-5310. PubMed ID: 32914879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
    Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
    Younes A; Kim S; Romaguera J; Copeland A; Farial Sde C; Kwak LW; Fayad L; Hagemeister F; Fanale M; Neelapu S; Lambert JM; Morariu-Zamfir R; Payrard S; Gordon LI
    J Clin Oncol; 2012 Aug; 30(22):2776-82. PubMed ID: 22753910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
    Galsky MD; Eisenberger M; Moore-Cooper S; Kelly WK; Slovin SF; DeLaCruz A; Lee Y; Webb IJ; Scher HI
    J Clin Oncol; 2008 May; 26(13):2147-54. PubMed ID: 18362364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
    Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
    Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.